60
Participants
Start Date
October 29, 2024
Primary Completion Date
May 31, 2028
Study Completion Date
November 30, 2029
Lifileucel
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with lifileucel, followed by IL-2.
RECRUITING
Roswell Park Cancer Institute, Buffalo
RECRUITING
Allegheny Health, Pittsburgh
RECRUITING
Orlando Health, Orlando
RECRUITING
H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa
RECRUITING
UofL Health - Brown Cancer Center, Louisville
RECRUITING
Barbara Ann Karmanos Cancer Hospital, Detroit
RECRUITING
Avera Medical Group Oncology, Sioux Falls
RECRUITING
University of Oklahoma, Oklahoma City
RECRUITING
MD Anderson Cancer Center - U of Texas, Houston
RECRUITING
University of Southern California, Los Angeles
Lead Sponsor
Iovance Biotherapeutics, Inc.
INDUSTRY